Speaker: Dr. Qingcong Lin, CEO, Biocytogen Boston Corporation, Biocytogen Boston Corp
Time: 9:30 am EDT, May 2nd
Talk title: Generation of Fully Human Antibodies for HLA-Peptide Complexes Using HLA Transgenic RenMice
The in vivo complexity of B cell differentiation, selection, and affinity maturation cannot be recapitulated in vitro. To facilitate therapeutic antibody discovery, several strains of humanized immunoglobulin mice were engineered, including a common human light chain model for bispecific/multispecific antibody discovery, drug target knockout mice to induce hyperimmunity, and an HLA-transgenic model for discovery of TCR-mimic antibodies. Together, these platforms serve to uncover best-in-class or first-in-class antibodies for novel targets.
Now in its eighteenth year, the PEGS Boston Summit is recognized as the leading international meeting place for the biotherapeutics community. PEGS Boston highlights a wide spectrum of biologic drug development with in-depth presentations on protein and antibody engineering, immunotherapy, oncology, expression, analytical, immunogenicity, and more.